# Invest today before our community round closes permanently. | Sempresto

- Canonical URL: https://wefunder.com/feed/441532
- Entity ID: wefunder:feed_item:441532
- Published at: 2026-10-30 13:00:00 UTC
- Updated at: 2026-10-30 13:00:02 UTC

## Author
Elizabeth Reczek

## Subject
Sempresto

## Content
Investors like you are helping bring our product through development and into the hands of patients. A reminder of what’s brought us to this point:🏆 Our expert team has led 3 IPOs and 30+ business development transactions across medtech, pharma, and biotech🎓 We're partnered with Thomas Jefferson University, home to the physician who invented this technology📈 A $3B+ addressable market, with 33 million Americans living with food allergies📱 A companion app and 24/7 telehealth model being engineered into the product from day one🔒 15 issued patents and 10 pending, covering smartphone-autoinjector integration across multiple emergency rescue medicines✅ Held a Type B Pre-IND meeting with FDA and received FDA’s written responses regarding our plan to pursue the 505(b)(2) pathway🏅 Winner of a 2026 Red Dot Design Award (past winners include Apple and BMW)💬 92% of patients and parents surveyed would choose Sempresto over their current autoinjector💉 A platform being built to expand beyond epinephrine into other emergency injectablesInvest or increase your investment today before our round closes : wefunder.com/sempresto With gratitude,LizElizabeth Reczek, PhDCo-Founder & CEO, SemprestoSempresto is an investigational product. It has not been approved by the FDA and is not available for sale.